Did Gilead (GILD) and Waxman Plan Meeting Ahead of Letter?
Tweet
Share
E-mailGet Alerts GILD Hot Sheet
Price: $149.78 +0.11%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
Revenue Growth %: -0.3%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
Revenue Growth %: -0.3%
Join SI Premium – FREE
Gilead Sciences Inc. (Nasdaq: GILD) is active today as one Bloomberg reporter thinks he has another take on the recent Waxman letter.
Drew Armstrong -- via his own Twitter account -- said Gilead execs had a meeting scheduled with Waxman all along and the letter just seemed like Waxman was making an effort to
Drew Armstrong -- via his own Twitter account -- said Gilead execs had a meeting scheduled with Waxman all along and the letter just seemed like Waxman was making an effort to
drag them in.You can read the full post here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Eledon files IND for islet cell trial, eyes Phase 3 kidney study
- Scholar Rock gets FDA fast track for apitegromab in rare muscle disease
- Teva's TEV '408 meets primary endpoint in celiac disease trial
Create E-mail Alert Related Categories
FDA, Insiders' BlogRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
